A different study about the impact of different antidiabetic agents on individuals with diabetes and COVID-19 showed that DPP4 inhibitors were highly possible to reduce COVID-19 mortality risk in individuals with diabetes [147]. This evidence concerns the gene DPP4 and COVID-19.